Can we harness the placebo effect to improve care in lower urinary tract dysfunction? ICI-RS 2019

V. Khullar*, M.S. Rahnama'i, N. Veit-Rubin, L. Cardozo, A.J. Wein

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

Abstract

The proposal "Can we harness the placebo effect to improve care in lower urinary tract dysfunction?" was discussed at the International Consultation on Incontinence-Research Society (ICI-RS) 2019 meeting. The placebo effect can change the treatment outcome whether the treatment is an active treatment or placebo. The total active treatment outcome is a combination of the placebo and the active treatment effect which is seen in placebo-controlled trials. The placebo effect plays an important role in the treatment of lower urinary tract dysfunction in overactive bladder, bladder pain syndrome, and stress urinary incontinence. In clinical practice, a number of factors can be employed to use the placebo effect to maximize its effect on patients receiving an active treatment, such as having the same environment for review such as the same appointment time, same room, and same clinician. Clinicians should also be aware of the nocebo effect which is increased with an overemphasis on side effects or negative outcomes.
Original languageEnglish
Pages (from-to)S80-S87
Number of pages8
JournalNeurourology and Urodynamics
Volume39
DOIs
Publication statusPublished - 1 Jul 2020

Keywords

  • bladder pain syndrome
  • clinical trials
  • clinical-trials
  • double-blind
  • drug trials
  • duloxetine
  • ethics
  • lower urinary tract symptoms
  • orally disintegrating tablet
  • overactive bladder
  • placebo
  • randomized controlled-trials
  • stress urinary incontinence
  • stress-incontinence
  • women
  • OVERACTIVE BLADDER
  • DULOXETINE
  • ORALLY DISINTEGRATING TABLET
  • ETHICS
  • RANDOMIZED CONTROLLED-TRIALS
  • DRUG TRIALS
  • WOMEN
  • CLINICAL-TRIALS
  • DOUBLE-BLIND
  • STRESS-INCONTINENCE

Cite this